Halozyme Therapeutics, Inc. (HALO) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $39.12 +0.38%
Revenue Growth %: +23.2%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
NLY, CP, RUSHA, More
Revenue Growth %: +23.2%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 loss of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $5.19 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme to Report First Quarter 2024 Financial and Operating Results
- SLM (SLM) Tops Q1 EPS by 20c; offers guidance
- QuantumScape (QS) Misses Q1 EPS by 1c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
